STOCK TITAN

Lexeo Therapeutics: Balyasny reports about 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) common stock is the subject of an amended beneficial-ownership report from Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC and Dmitry Balyasny. Each may be deemed to beneficially own the same 8,196,420-share position, approximately 9.99% of the class, based on 82,046,255 shares outstanding as of August 10, 2026.

The reported amount consists of 3,987,787 shares and 4,208,633 shares issuable upon exercise of 5,586,529 warrants. The warrants are subject to a Beneficial Ownership Limitation that prevents exercise to the extent it would cause the holder to beneficially own more than 9.99% of the shares outstanding. Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., the direct holders, have the right to receive dividends or sale proceeds from the reported securities.

Beneficially owned 8,196,420 shares Each of the five reporting persons may be deemed to own the same position.
Percentage of class Approximately 9.99% Based on 82,046,255 shares outstanding as of August 10, 2026.
Shares outstanding 82,046,255 shares As of August 10, 2026.
Shares not issuable upon warrant exercise 3,987,787 shares Part of the reported beneficial-ownership amount.
Shares issuable upon warrant exercise 4,208,633 shares Included in the reported beneficial-ownership amount.
Warrants 5,586,529 warrants Subject to the Beneficial Ownership Limitation.
Beneficial Ownership Limitation 9.99% Prevents warrant exercise to the extent it would cause ownership to exceed this level.
Beneficial Ownership Limitation regulatory
"subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
investment power regulatory
"voting and investment power over such Shares"
beneficially own regulatory
"may be deemed to beneficially own such Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXEO shares did the Balyasny reporting persons report owning?

The five reporting persons each may be deemed to beneficially own the same 8,196,420-share position, approximately 9.99% of the class. The reported amount is based on 82,046,255 shares outstanding as of August 10, 2026; the five persons' amounts are not separate positions.

How does the LXEO warrant ownership blocker work?

The reported amount includes 4,208,633 shares issuable upon exercise of 5,586,529 warrants. The warrants are subject to a Beneficial Ownership Limitation that prevents exercise to the extent it would cause the holder to beneficially own more than 9.99% of the shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





52886X107

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BALYASNY ASSET MANAGEMENT L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:11/16/2026

Keep reading